Clinical development of the GnRH agonist leuprolide acetate depot

Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive trea...

Descripción completa

Detalles Bibliográficos
Autor principal: Chwalisz, Kristof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Special Issue
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201295/
https://www.ncbi.nlm.nih.gov/pubmed/37223757
http://dx.doi.org/10.1016/j.xfre.2022.11.011
_version_ 1785045236349665280
author Chwalisz, Kristof
author_facet Chwalisz, Kristof
author_sort Chwalisz, Kristof
collection PubMed
description Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection.
format Online
Article
Text
id pubmed-10201295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102012952023-05-23 Clinical development of the GnRH agonist leuprolide acetate depot Chwalisz, Kristof F S Rep Special Issue Leuprolide acetate is the first GnRH agonist that entered clinical development after the discovery of the native GnRH. Several long-acting depot formulations of leuprolide acetate (ranging from 1-month to 6-month intramuscular injections) have been successively developed for various suppressive treatments in men, women, and children, which are available in the United States and globally. This mini review aims to summarize the key clinical studies that led to regulatory approval of leuprolide acetate depot suspension for injection. Elsevier 2022-11-21 /pmc/articles/PMC10201295/ /pubmed/37223757 http://dx.doi.org/10.1016/j.xfre.2022.11.011 Text en © 2022 The Author https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Special Issue
Chwalisz, Kristof
Clinical development of the GnRH agonist leuprolide acetate depot
title Clinical development of the GnRH agonist leuprolide acetate depot
title_full Clinical development of the GnRH agonist leuprolide acetate depot
title_fullStr Clinical development of the GnRH agonist leuprolide acetate depot
title_full_unstemmed Clinical development of the GnRH agonist leuprolide acetate depot
title_short Clinical development of the GnRH agonist leuprolide acetate depot
title_sort clinical development of the gnrh agonist leuprolide acetate depot
topic Special Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201295/
https://www.ncbi.nlm.nih.gov/pubmed/37223757
http://dx.doi.org/10.1016/j.xfre.2022.11.011
work_keys_str_mv AT chwaliszkristof clinicaldevelopmentofthegnrhagonistleuprolideacetatedepot

Ejemplares similares